Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients

Lung transplant recipients have an increased risk for severe coronavirus disease 2019 (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A third dose of a SARS-CoV-2 vaccine has been recommended for all solid organ transplant recipients, but data from lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, T.W., Meek, B., Rijkers, G.T., van Kessel, D.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978449/
https://www.ncbi.nlm.nih.gov/pubmed/35390480
http://dx.doi.org/10.1016/j.trim.2022.101599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978449/
https://www.ncbi.nlm.nih.gov/pubmed/35390480
http://dx.doi.org/10.1016/j.trim.2022.101599

Ejemplares similares